ESR1 and neoplasm: Resistance to endocrine therapies is complicated process that involves epigenetic alterations in the ESR1 gene, alternative splicing events, post-translational alterations and altered recruitment of co-regulators of ER; it also affects the tumor milieu and several other mechanisms [120].